A groundbreaking AI tool has just been approved by the U.S. Food and Drug Administration (FDA) to help doctors detect fetal abnormalities that traditional ultrasounds often miss. Developed by the American start-up BioticsAI, the software works alongside existing ultrasound machines, analysing images in real-time and alerting doctors to potential issues during pregnancy scans.
How the AI Enhances Ultrasounds
Prenatal ultrasounds are essential for monitoring a baby’s development, but even routine scans can overlook serious conditions. BioticsAI’s software immediately evaluates each image, suggesting improvements for better clarity and checking that every part of the fetus is visible. It can flag missing or unclear sections and, using patterns learned from global data, detect potential problems like heart defects or limb abnormalities.
After the scan, the AI generates a detailed report that doctors can review, streamlining documentation and saving an estimated eight minutes per patient. This real-time analysis gives clinicians an extra layer of accuracy, helping them identify issues that might otherwise go unnoticed.
Closing Gaps in Prenatal Care
Congenital anomalies affect roughly 24 out of every 10,000 births in Europe. Research from Cochrane, which reviewed over seven million pregnancies, shows that a single early scan detects only 38% of birth defects, while a mid-pregnancy scan catches 51%. Performing both scans raises detection to 84%, but some conditions still slip through the cracks. Tools like BioticsAI aim to close that gap, offering more reliable early warnings for families and doctors alike.
AI Solutions Expanding Worldwide
The U.S. isn’t alone in adopting AI for prenatal care. European companies such as Diagnoly and Sonio Detect have also created AI-assisted ultrasound systems, helping doctors automatically identify fetal structures and heart problems. As these technologies spread, they promise to make prenatal screening safer, faster, and more precise for expectant parents everywhere.
